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ABSTRACT: Deletion of F508 in the ﬁrst nucleotide binding domain (NBD1) of cystic ﬁbrosis transmembrane
conductance regulator protein (CFTR) is the commonest cause of cystic ﬁbrosis (CF). Functional interactions
between CFTR and CK2, a highly pleiotropic protein kinase, have been recently described which are
perturbed by the F508 deletion. Here we show that both NBD1 wild type and NBD1 ∆F508 are
phosphorylated in vitro by CK2 catalytic R-subunit but not by CK2 holoenzyme unless polylysine is
added. MS analysis reveals that, in both NBD1 wild type and ∆F508, the phosphorylated residues are
S422 and S670, while phosphorylation of S511 could not be detected. Accordingly, peptides encompassing
the 500-518 sequence of CFTR are not phosphorylated by CK2; rather they inhibit CK2R catalytic activity
in a manner which is not competitive with respect to the speciﬁc CK2 peptide substrate. In contrast,
500-518 peptides promote the phosphorylation of NBD1 by CK2 holoenzyme overcoming inhibition by
the  -subunit. Such a stimulatory efﬁcacy of the CFTR 500-518 peptide is dramatically enhanced by
deletion of F508 and is abolished by deletion of the II507 doublet. Kinetics of NBD1 phosphorylation
by CK2 holoenzyme, but not by CK2R, display a sigmoid shape denoting a positive cooperativity which
is dramatically enhanced by the addition of the ∆F508 CFTR peptide. SPR analysis shows that NBD1
∆F508 interacts more tightly than NBD1 wt with the R-subunit of CK2 and that CFTR peptides which
are able to trigger NBD1 phosphorylation by CK2 holoenzyme also perturb the interaction between the
R- and the  -subunits of CK2.
By far, the most common cause of cystic ﬁbrosis is the
deletion of a single amino acid, phenylalanine 508 (∆F508), in
the nucleotide binding domain-1 (NBD1) of the cystic ﬁbrosis
transmembrane conductance regulator (CFTR).
1 CFTR is an
ion channel belonging to the ATP-binding cassette (ABC)
family of transmembrane pumps, but unlike other family
members, CFTR displays no known pump activity (1). Protein
phosphorylation and adequate nucleotide levels play a key role
in the control of CFTR channel function, particularly activation
by PKA, augmentation by PKC (2), and inhibition by
AMPK (3, 4), but their interactions are complex and incom-
pletely understood (5). This complexity arises in part from many
observations suggesting that CFTR is part of a multimolecular
complex in the apical membrane of epithelial cells containing
(besides protein kinases) N-terminal inhibitory syntaxins, PKA-
interacting ezrin binding phosphoprotein (6), and many others
including CAP 70 (7) and more recently a cAMP-efﬂux pump
binding at the C-terminus of CFTR (8). When CFTR is puriﬁed
to homogeneity, F508 deletion by itself, albeit causing a
signiﬁcant gating defect (9), neither prevents CFTR activity as
chloride channel (10) nor affects ATP binding by NBD1, whose
overall structure is unlikely to critically rely on F508 because
this residue is located in a ﬂexible loop on the periphery of the
domain structure remote from the ATP binding site (11).
Nevertheless, this mutation leads to reduced CFTR channel
function with current models suggesting poor retention in the
plasma membrane after loss of F508 (12). This may result from
improper folding (13) and instability of CFTR whose suscep-
tibility to the protein degradation machineries is therefore
increased (14, 15). One school of thought suggests that less
than 1% of the ∆F508 CFTR reaches the membrane, where it
can display some attenuated activity (9), while this ﬁgure in
the case of wild-type CFTR can approach 75% in some cell
types and culture conditions (16). There are some dissenting
views (15) and even the well established idea that CFTR devoid
of F508 fails to fold has recently been challenged (17).
A possible alternative explanation for the dramatic effects
of F508 deletion could be that this residue is directly or
indirectly implicated in interactions between CFTR and the
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Published on Web 07/03/2008network of proteins committed, on the one hand, to its proper
folding and processing and, on the other, to its unfolding
and degradation. Alternatively, F508 might be important for
the interaction with a regulatory protein given its accessible
location in NBD1. The latter idea might provide a means to
explain the multisystem nature of cystic ﬁbrosis provided
the regulatory protein has multiple targets. Pertinent to this
could be the observation by Treharne et al. (18) that F508 is
in the close proximity to a candidate phosphoacceptor
residue, S511, located within a consensus sequence for the
protein kinase CK2. CK2 is a highly pleiotropic protein
kinase which recognizes seryl and threonyl residues speciﬁed
by an acidic side chain at position n + 3, whose seemingly
endless repertoire of substrates includes many molecules
implicated in protein synthesis, folding, and degradation (19).
CK2 has a complex structure. In general, CK2 catalytic
subunits (R and/or R′) are active either alone or when
combined with a dimer of two regulatory  -subunits that give
rise to its hetrotetrameric holoenzyme which is the most
common form of CK2 found in the cell. In a few cases
however, as exempliﬁed by calmodulin, substrate phospho-
rylation is actually prevented by association with the
 -subunits (“class II” substrates (20)). CK2 is invariably
elevated in tumors, and it appears to play a global antiapo-
ptotic role, suggesting that it might represent a valuable target
for anticancer agents (21, 22). There is an unexplained excess
of cancer in young CF patients (23).
The proximity of the putative CK2 site S511 to the crucial
F508 in CFTR prompted Treharne et al. to investigate links
between CK2 and CFTR functionality (24). Using immu-
nohistochemistry and electrophysiology, they proposed that
CK2 colocalizes with wild-type CFTR but not with its ∆F508
mutant at the apical membranes of epithelial cells. Using
the single channel conﬁguration of the patch-clamp tech-
nique, CK2 inhibitors induced prompt (within 80 s) closure
of CFTR chloride channel function, but crucially, closure
was only observed when CFTR was in its native “cell
attached” environment (and not when excised from the cell,
presumably disrupted from its normal protein associates).
They also provided in vitro preliminary data showing that
CK2 is able to phosphorylate NBD1 better than NBD1
∆F508 and much less a NBD1 mutant in which S511 was
mutated to alanine. All these experiments were run with CK2
holoenzyme and were not corroborated by kinetic data nor
by an analysis of physical interactions between individual
CK2 subunits and NBD1, either wild type or ∆F508. This
prompted us to undertake an analysis of mechanist features
underlying NBD1 phosphorylation by CK2. The work
presented here led to the unanticipated ﬁnding that, when
NBD1 is the substrate, its phosphorylation is inhibited by
the  -subunits of CK2 and CK2 phosphorylates serines 422,
423, and 670, but not to any appreciable extent Ser-511.
Surprisingly, synthetic peptides encompassing the 500-518
CFTR sequence are able to trigger the activity of CK2
holoenzyme toward NBD1 in an F508-dependent manner.
These data disclose new and unexpected perspectives about
the implication of CK2 in CF pathogenesis by invoking the
notion that F508 in CFTR controls CK2 activity in a complex
manner.
EXPERIMENTAL PROCEDURES
Materials. Polylysine (Mr 47000) and most of the reagents
were purchased from Sigma. Puriﬁed wild-type and ∆F508
mutated recombinant murine NBD1 (spanning sequence
389-673) and wild-type human NBD1 (spanning sequence
389-673) were generously provided by the Philip J. Thomas
laboratory (Southwestern Medical Center, University of
Texas, Dallas, TX; http://www4.utsouthwestern.edu/tho-
maslab/). Recombinant R- and  -subunits of human protein
kinase CK2 were expressed in Escherichia coli and puriﬁed
as previously described (25). Native CK2 was puriﬁed from
rat liver (26).
Peptide Synthesis. The CFTR-derived synthetic peptides
were prepared by the solid-phase peptide synthesis method
using an automatized peptide synthesizer (model 431-A;
Applied Biosystems, Foster City, CA) as C-terminal acids
on HMP resin (Applied Biosystems) or as C-terminal amides
on Rink Amide PEGA resin (Novabiochem, Bad Soden,
Germany). The ﬂuoren-9-ylmethoxycarbonyl (Fmoc) strategy
(27) was used throughout the peptide chain assembly. The
NR-Fmoc amino acids carrying standard side chain protective
groups were converted to benzotriazolyl esters with 1-hy-
droxybenzotriazole (HOBt) and 2-(1H-benzotriazol-1-yl)-
1,1,3,3-tetramethyluronium hexaﬂuorophosphate (HBTU).
N-Terminal acetylation was performed on the peptidyl-resin
using acetic anhydride. Cleavage of the peptides was
performed by reacting the peptidyl resins with a mixture
containing TFA/H2O/thioanisole/ethanedithiol/phenol (10
mL/0.5 mL/0.5 mL/0.25 mL/750 mg) for 2.5 h. Crude
peptides were puriﬁed by a preparative reverse-phase HPLC.
Molecular masses of the peptides were conﬁrmed by mass
spectroscopy with direct infusion on a Micromass ZMD-
4000 mass spectrometer (Waters-Micromass). The purity of
the peptides was about 95% as evaluated by analytical
reverse-phase HPLC.
Phosphorylation Assay. In vitro phosphorylation of NBD1
proteins and of the NBD1-derived synthetic peptides was
performed by incubating substrates (ﬁnal volume 25 µL) in
a medium containing 50 mM Tris-HCl, pH 7.5, 12 mM
MgCl2, 100 mM NaCl, and 100 µM[ γ-33P]ATP (speciﬁc
radioactivity 2000-4000 cpm/pmol) in the presence of CK2R
catalytic subunit (8-28 nM) or CK2 holoenzyme (0.8-4.8
nM). In some experiments polylysine (330 nM) was added.
The concentration of NBD1 was 3.5 µM unless differently
speciﬁed in ﬁgure legends. The reaction was stopped by
addition of Laemmli buffer and subjected to SDS-PAGE.
Protein samples were visualized by staining with Coomassie
Brilliant Blue or, alternatively, transferred onto nitrocellulose
membranes and stained with Ponceau red dye. Dried gels or
membranes were then exposed to storage phosphor screens
overnight, which were subsequently scanned by the Cyclone
Storage Phosphor System (Packard). After scanning was
complete, a resulting digitized image could be viewed and
analyzed by the Optiquant software, which expresses radio-
activity as digital light units (DLU). Whenever phosphate
incorporation into protein substrates was required to assess
catalytic efﬁciency, the relationship between the DLUs and
33P cpm was deduced by spotting known amounts of
γ-[33P]ATP (speciﬁc activity 7000 Ci/mmol) in triplicates
on ﬁlter paper, which were dried and exposed to the phosphor
screen together with the sample. From the DLU values and
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DLU was calculated and the radioactivity at selected ﬁelds
assessed. Alternatively, the bands corresponding to the
protein of interest on nitrocellulose membranes were excised
and subjected to liquid scintillation counting.
Phosphopeptide Enrichment and MS Analysis. After in
vitro phosphorylation of NBD1, the protein (8 µg) was run
on a SDS-PAGE, and the gel bands were cut and subjected
to reduction/alkylation and in-gel digestion using sequencing
grade modiﬁed trypsin (Promega, Madison, WI). Brieﬂy, gel
bands were crushed, washed with acetonitrile, dried under
vacuum, and treated with 10 mM DTT in 100 mM NH4HCO3
f o r1ha t5 6°C. The DTT solution was then removed and
the gel pieces were further treated with 55 mM iodoaceta-
mide (in 100 mM NH4HCO3) for 45 min in the dark. After
extensive washing with 100 mM NH4HCO3 and acetonitrile,
the gels pieces were dried and ﬁnally treated with 12.5 ng/
µL trypsin at 37 °C overnight. After digestion, the peptides
were extracted by three changes of 50% acetonitrile/0.1%
formic acid (20 min between changes), dried under vacuum,
and resuspended with 10 µL of 0.1% formic acid.
Phosphopeptides were enriched on TiO2 microcolumns as
previously described (28).
The phosphopeptide enriched samples were analyzed using
a LCQ XP (Thermo Electron, San Jose ´, CA) interfaced with
a nano-LC system 1100 series (Agilent Technologies, Santa
Clara, CA) and a capillary column Zorbax 300SB C18, 3.5
µm, 150 mm × 75 µm (Agilent), using a linear gradient of
acetonitrile/0.1% formic acid from 5% to 40% in 20 min.
Data were acquired in a data-dependent mode: a full MS
scan was followed by a Zoom scan and a MS/MS scan on
the three most intense peaks. MS/MS data were searched
using Mascot (Matrix Science, London, UK) against the
mouse section of the IPI database (version 3.31, 56555
entries). Enzyme speciﬁcity was set to trypsin with one
missed cleavage using carbamidomethylcysteine as ﬁxed
modiﬁcation and phosphorylation of S/T/Y as variable
modiﬁcation. The tolerance of the precursor ion was set to
1 mass unit for both peptide and fragment ion matches. All
of the MS/MS spectra were then carefully inspected to
conﬁrm the identiﬁcations, and many of them had to be
manually interpreted to correctly assign the position of the
phospho residue(s).
SPR Analysis. BIAcoreX system was used to detect and
determine the kinetic constants of the interactions. CK2R
and CK2  subunits were covalently linked to sensor chips
CM5 (BIAcore) using amine coupling chemistry (29).
Solutions of the interacting proteins, NBD1 wt and NBD1
∆F508 (“analyte”), were injected with a ﬂow rate of 10 µL/
min at 25 °C in HBS running buffer (10 mM Hepes, pH
7.4, 150 mM NaCl, 3 mM EDTA, 0.005% (v/v) surfactant
P20). The response obtained with a control surface (without
immobilized protein) was subtracted to each sensorgram. The
kinetic data were interpreted according a simple 1:1 binding
model, and the rate constants of the interactions were
calculated using the SPR kinetic evaluation software BIAe-
valuation 3.0 (BIAcore).
RESULTS
The phosphorylation of mouse wild-type, mouse ∆F508,
and human wild-type CFTR nucleotide binding domain 1
(NBD1) by protein kinase CK2, either catalytic subunit or
reconstituted holoenzyme, is shown in Figure 1A: mouse
NBD1 ∆F is phosphorylated by CK2R slightly better than
its wild-type counterpart which in turn is phosphorylated
more readily than the wild-type human homologue. Phos-
phorylation is abolished in all cases if the catalytic subunits
of CK2 are combined with the  -subunits to form CK2
holoenzyme. The latter is in fact inactive toward all NBD1
forms unless polylysine is present. Polylysine overcomes
downregulation by the  -subunit and stimulates NBD1 (wild
type and ∆F508) phosphorylation by the holoenzyme beyond
the level observed with the catalytic subunit alone. Addition
of polylysine to the R-subunit alone has no signiﬁcant effect
(not shown). Kinetic analyses of murine wild-type vs ∆F508
NBD1 phosphorylation by CK2 R-subunit show that they
display a similar behavior (Figure 1B). Kinetics performed
with CK2 holoenzyme plus polylysine (Figure 1C) are also
FIGURE 1: Phosphorylation of wild-type and ∆F508 mutated NBD1
by protein kinase CK2. In (A) 3 µg of murine and human NBD1
were incubated under conditions decribed in the Experimental
Procedures with CK2R catalytic subunit either alone (lane 1) or
previously combined with equimolar amounts of CK2  regulatory
subunit in the absence (lane 2) or in the presence of 330 nM
polylysine (lane 3). Only the autoradiograms are shown. In (B)
and (C) the kinetics of phosphorylation by CK2 catalytic subunit
and by CK2 holoenzyme, respectively, at increasing concentration
of NBD1 wild type (O) and ∆F508 (b) are illustrated. The data
represent the means obtained from experiments run in triplicate
with SD never exceeding 15%.
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that the apparent Km values in this case are higher than those
calculated with CK2R, especially due to a sigmoid shape of
the ﬁrst part of the saturation curves.
To identify the residues phosphorylated by CK2, NBD1
either wild type or ∆F508 were exaustively phosphorylated
by CK2 holoenzyme in the presence of polylysine, and the
phosphorylated residue(s) was (were) identiﬁed by tryptic
digestion followed by MS analysis as detailed in the
Experimental Procedures. The results summarized in Figure
2 led to the unambiguous identiﬁcation of peptides including
three phosphorylated residues: pS422, either alone or together
with pS423, and pS670. Both S422 and S670 display the
typical CK2 consensus, while S423 does not. Note however
that no peptides including pS423 alone could be found,
suggesting that the phosphorylation of S423 is primed or at
least facilitated by previous phosphorylation of S422. Indeed,
seryl residues ﬂanked by a phosphorylated and a carboxylic
side chain are known to become susceptible to CK2 (30). In
human NBD1 S422 is conserved but S423 is not, and the
sequence around S670 is altered. This may account for its
reduced phosphorylation as compared to mouse NBD1 (see
Figure 1A). S422 was also found to be the main or the only
phosphorylated residue whenever NBD1 wild type and
∆F508 were phosphorylated by CK2 holoenzyme activated
by stimulatory peptides (see below) instead of polylysine
(see Figure 2). A remarkable and recurrent outcome of our
MS analyses was the failure to detect any trace of phospho-
FIGURE 2: MS analysis of NBD1 phosphorylation sites by protein kinase CK2. Phosphorylation of mouse wild-type NBD1 by CK2 holoenzyme
in the presence of polylysine and elution of the radiolabeled bands from the SDS-PAGE gel were performed as described in the Experimental
Procedures. (A) List of identiﬁed phosphopeptides. Experimental mass, charge state of the peptides, theoretical mass, and delta mass are
listed with the peptide sequence. The position of the phospho residue is marked with an asterisk. Note the presence of several semitryptic
peptides probably due to a contamination with chymotrypsin. (B) Annotated fragmentation spectra of the phosphopeptides HS*SDENNVSFSH
(left panel) and HS*S*DENNVSFSH (right panel). For the monophosphorylated peptide the position of the phosphoresidue is clearly
indicated by the transition y10-y11, while for the bisphosphorylated peptide are very clear the transitions y9-y10 and y10-y11 that indicate
the positions of the two phosphoserines. Both spectra are dominated by the neutral losses of H3PO4 from the parent ion. The label ∆
indicates the fragments originated by the neutral loss of phosphate.
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(S511YDE), despite the proposal that this was the ﬁrst
candidate for phosphorylation by CK2 (24). Lack of phos-
phorylated S511 was also consistent with failure of synthetic
peptides encompassing the 500-518 CFTR sequence (listed
in Figure 4) to undergo appreciable phosphorylation by either
CK2R or CK2 holoenzyme plus polylysine. Neither the
deletions of six and nine N-terminal residues nor substitution
in the deleted 509-518 peptide of two downstream arginines
(R516, R518), in the attempt to remove potentially negative
determinants, was able to promote any signiﬁcant phospho-
rylation of S511 peptides by CK2. A weak phosphorylation,
negligible compared to full-length NBD1, however, was
observed upon substitution of Tyr-512, a potential target for
the Syk tyrosine kinase (31) with phosphotyrosine (peptide
5 in Figure 4) (not shown).
A possible explanation for the failure of the 500-518
peptide to undergo appreciable phosphorylation by CK2
despite the presence in it of the proper consensus sequence
was that its phospho product is not easily released from the
kinase, a circumstance frequently observed with peptide
substrates of protein kinases (ref 32 and references therein).
Such behavior reﬂects in the aptitude of such peptides to
act as competitive inhibitors. We therefore examined the
potential of the CFTR 500-518 peptide to inhibit the
phosphorylation of NBD1 full length by CK2R. We found
that, although at high peptide concentration (400 µM) the
expected inhibition could be observed, at lower concentra-
tions the peptide rather displayed a slight stimulatory effect
which was more signiﬁcant if the peptide had the F508
deletion (Figure 3A). This stimulatory effect was much more
remarkable if CK2R was replaced by the holoenzyme, given
that the latter alone (i.e., no polylysine present, Figure 1) is
unable to phosphorylate NBD1 by itself. In this case,
therefore, the peptide promotes a de noVo phosphorylation
of NBD1 which otherwise would be undetectable (Figure
3B), thus partially mimicking polylysine in this respect (see
Figure 1). Again the ∆F508 peptide was more effective than
the wild type in terms of both higher efﬁcacy at lower
concentration and overall phosphorylation increment. Note
that in the case of the holoenzyme-mediated phosphorylation
no inhibition could be observed even by increasing the
concentration of the peptides to 800 µM. At such high
concentration the stimulatory efﬁcacy of the ∆F508 peptide
and, to a lesser extent, of the wt peptide markedly declined.
Similar data were obtained if the recombinant holoenzyme
FIGURE 3: Dose-dependent effect of NBD1-derived synthetic
peptides on the phosphorylation of NBD1 by protein kinase CK2.
Phosphorylation of wild-type murine NBD1 (3 µg) was performed
by CK2 catalytic subunit (panel A) and by CK2 holoenzyme (panel
B) as described in the Experimental Procedures in the presence of
increasing concentration of the NBD1-derived wild-type GTIK-
ENIIFGVSYDEYRYR (O) and ∆F508 mutated GTIKENIIGVSY-
DEYRYR (b) peptides. The insets show the corresponding
autoradiograms. The arrow indicates the position of NBD1. The
data represent the means obtained from experiments run in triplicate
with SD never exceeding 15%.
FIGURE 4: Effect of variable substitutions within the NBD1-derived
peptides on their stimulatory efﬁcacy on NBD1 phosphorylation
by CK2 holoenzyme. Murine NBD1 (3 µg) was phosphorylated
by CK2 holoenzyme under conditions described in the Experimental
Procedures in the presence of variably substituted peptides (160
µM) listed in (A). In (B) the SDS-PAGE corresponding autora-
diograms are shown with arrows indicating the position of the
NBD1 protein and of the autophosphorylated CK2  subunit,
respectively. In (C) the quantitation of NBD1 radiolabeling with
respect to the control in the absence of peptides (C) is reported as
histograms. Numbering refers to the list reported in (A).
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liver (not shown).
In an attempt to gain insight into structural features
responsible for the stimulatory efﬁcacy of the CFTR
500-518 peptides, a number of derivatives bearing deletions
and/or substitutions were synthesized and tested for their
ability to promote the phosphorylation of NBD1 by CK2
holoenzyme. The data, summarized in Figure 4, show that
the ﬁrst six residues of the peptide GTIKENIIFGVSYDEY-
RYR can be deleted without abrogating the stimulatory
efﬁcacy of the peptide. This stimulation is lost however if
the ﬁrst nine residues are deleted, thus disclosing the crucial
role of the IIF508 triplet. On the other hand, the single deletion
of F508 either in the parent peptide (500-518) or in its
shortened derivative (506-518) enhances stimulation. A
similar effect is observed if F508 is replaced by the smaller
residue alanine, while its replacement with cysteine, a
naturally occurring polymorphism devoid of the pathological
consequences displayed by the ∆F508 mutation, has no
effect. The crucial role of the 508 position is further
highlighted by the ﬁnding that the stimulatory efﬁcacy is
decreased if F508 is replaced by the bulkier side chain of a
tryptophan. On the other hand, the replacement of the
potential CK2 target S511 by alanine (which does not occur
naturally as S511 is conserved) signiﬁcantly increases the
stimulatory potency of the peptide. It may be pertinent to
note that the efﬁcacy of the peptides as stimulators of NBD1
phosphorylation correlates with their inhibition of CK2
autophosphorylation at its  -subunit (see lower bands in
Figure 4B, for example), an event which is symptomatic of
CK2 holoenzyme supramolecular organization (33). In
contrast, no correlation with susceptibility to phosphorylation
could be observed, given the inability of all the peptides listed
in Figure 4A, with the only partial exception of the
phosphopeptide 5 (devoid of any stimulatory efﬁcacy) to
undergo phosphorylation by CK2 (see also above).
Next we wanted to see if stimulation of CK2 holoenzyme
by the CFTR 500-518 peptide and its ∆F508 derivative was
a general property or was only evident with NBD1 and
possibly other substrates whose phosphorylation is inhibited
by the  -subunit (“class II” according to previous nomen-
clature (20)). To this purpose the efﬁcacy of the peptides
was evaluated using the following phosphoacceptor sub-
strates: mouse NBD1, calmodulin, inhibitor-2 of protein
phosphatase 1 (I-2), heat shock protein 90 (HSP90), and a
speciﬁc peptide substrate of CK2 (R3AD2SD5). As shown
in Figure 5A only in the case of NBD1 and calmodulin (the
typical representative of class II substrates) was phospho-
rylation inhibited by the  -subunit, and in both cases it was
restored by addition of the peptide. As in the case of NBD1,
calmodulin phosphorylation is increased more efﬁciently by
using the ∆F508 peptide instead of the wild-type CFTR
peptide. In contrast, phosphorylation of I-2, HSP90, and the
peptide substrate was not inhibited by the  -subunit, and no
stimulation by the NBD1 wild-type peptide could be
observed. However, a signiﬁcant, near doubling, stimulation
by the ∆F508 peptide was also evident with I-2 and HSP90
over and above that exerted in these cases by the  -subunit
alone. It can be concluded therefore that only the phospho-
rylation of a subset of CK2 substrates whose phosphorylation
is downregulated by the  -subunit alone is dramatically
enhanced by the CFTR 500-518 segment acting differen-
tially in an F508-dependent manner. The ﬁnding that the
stimulatory effect of the  -subunit on the phosphorylation
of the other substrates by CK2 holoenzyme is not decreased
by the CFTR 500-518 wt peptide while being actually
increased by the ∆F508 peptide would indicate that these
peptides do not abrogate all the functions of the  -subunit,
but only its downregulatory potential (compare the second
and fourth bars for each protein substrate shown in Figure
5A).
Additional evidence supporting the crucial role of the
 -subunit to mediate upregulation of CK2 activity by the
CFTR-derived peptides came from experiments in which
these peptides were tested for their ability to inﬂuence the
phosphorylation of different substrates by CK2 R-subunit
alone rather than by CK2 holoenzyme. Under these condi-
tions as anticipated in Figure 3 NBD1 phosphorylation was
affected in opposite ways depending on the peptide’s
concentration, being stimulated at low concentration (around
100 µM) while inhibited at concentrations higher than 300
µM. In this respect, as shown in Figure 5B, only the
phosphorylation of I-2 is reminiscent of NBD1 with a
signiﬁcant stimulation at 80 µM peptide and inhibition at
400 µM. With all of the other substrates the peptides were
ﬂatly inhibitory already at 80 µM. Concentrations below 80
µM were also tested and never found to display signiﬁcant
stimulatory efﬁcacy (not shown). It has to be concluded
therefore that the isolated catalytic subunit of CK2 generally
is more susceptible to inhibition rather than to stimulation
by the CFTR 500-518 peptides, the only exceptions being
provided by the protein substrates NBD1 and I-2 at low
peptide concentration. The drastic inhibition observed using
the speciﬁc CK2 peptide substrate is especially remarkable
considering that no inhibition at all is observed if the same
experiment is run with CK2 holoenzyme (see Figure 5A).
This suggests that inhibition is not merely due to pseudosub-
strate effect. Accordingly, kinetics run with CFTR 500-518
peptides, either wild type or ∆F508 (Figure 5C), are
consistent with a purely noncompetitive mechanism of
inhibition. Collectively, our data strongly suggest that the
allosteric site(s) on the R-subunit where the CFTR peptides
bind is (are) no longer easily accessible in the holoenzyme.
Since the stimulatory efﬁcacy of the CFTR peptides
observed with CK2 holoenzyme is more pronounced if they
bear the F508 deletion which is the most common cause of
cystic ﬁbrosis, it seems likely that these mutant peptides are
better shaped to counteract the interactions with the  -subunit
that are normally responsible for downregulation of CK2R.
This point of view was further supported by kinetic experi-
ments run with CK2 holoenzyme by increasing NBD1
concentration either in the absence or in the presence of the
stimulatory peptides CFTR 500-518 wild type and ∆F508.
As shown in Figure 6A, at all concentrations tested,
holoenzyme-induced phosphorylation of NBD1 alone is
negligible as compared to phosphorylation evoked by the
addition of CFTR peptides, being even less pronounced than
autophosphorylation of CK2 at its  -subunit. This latter is
reduced or even suppressed by the addition of peptides
(Figure 6B) with a concomitant striking increase in catalytic
activity that highlights a positive cooperative effect of NBD1
(Figure 6B). Such behavior, revealed by the sigmoidicity of
the curve, is especially pronounced if the stimulatory peptide
bears the F508 deletion. In this case, by raising the NBD1
7930 Biochemistry, Vol. 47, No. 30, 2008 Pagano et al.FIGURE 5: Variable modulation of CK2 holoenzyme (A) and CK2R (B) by wild-type and ∆F508 mutated NBD1 500-518 peptides. Evidence
for an allosteric mechanism (C). Phosphorylation conditions by CK2R catalytic subunit and by the in vitro reconstituted holoenzyme are
described in the Experimental Procedures. The substrate concentrations were 3.5, 5, 2.5, 0.5, and 100 µM for NBD1, calmodulin (CaM),
inhibitor-2 of protein phosphatase 1 (I-2), HSP90, and peptide RRRADDSDDDDD, respectively. The data represent the means of at least
three independent experiments with SD never exceeding 15%. (A) Effect of NBD1 peptides (80 µM) on the CK2 holoenzyme-mediated
phosphorylation of the indicated substrates. (B) Effect of increasing concentrations of NBD1-derived peptides (as indicated) on CK2R
catalytic subunit activity toward the indicated substrates. (C) Kinetic analysis of the mechanism of inhibition of CK2R by CFTR 500-518
∆F508. Kinetics of the speciﬁc CK2 peptide substrate (RRRADDSDDDDD) phosphorylation by CK2R were either in the absence (9)o r
in the presence of CFTR 500-518 ∆F508 peptide at either 10 µM( 2)o r3 0µM( 1).
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a value about 5-fold higher than in the presence of the wild-
type F508-bearing peptide. This rate (about 6 nmol of
P·min-1·mg-1 of CK2 holoenzyme) is comparable to those
of typical CK2 substrates, notably calmodulin tested under
identical conditions (about 8 nmol of P·min-1·mg-1 of CK2;
see Figure 6D). In contrast, at low NBD1 concentration (2
µM or less) the phosphorylation rate in the presence of the
wild-type peptide is actually higher than that observed with
the ∆F508 peptide. Similar results were obtained if human
instead of mouse NBD1 was used as phosphorylatable
substrate (Figure 6C) although in this case the phosphory-
lation rate was about 3-fold lower and in the absence of
peptides it was not detectable at all (not shown). Note that
cooperativity was absent or modest when kinetics were run
with the isolated catalytic subunit or with the holoenzyme
activated by polylysine rather than by the CFTR peptides
(see Figure 1). No cooperativity at all was observed if
calmodulin was the substrate of CK2 holoenzyme activated
by either polylysine (not shown) or the CFTR 500-518
∆F508 peptide (Figure 6D). Collectively taken, these results
provide the evidence that cooperative phosphorylation by
CK2 is a unique property of CFTR NBD1, requiring the
heterotetrameric structure of CK2 holoenzyme and promoted
by fragments encompassing the CFTR 500-518 segment,
with special reference to those bearing the F508 deletion.
To provide an independent line of evidence that NBD1,
and disease relevantly, its ∆F508 mutant, may exert an
allosteric regulation of CK2, their ability to physically
interact with CK2 subunits was assessed by the SPR
technique using surface plasmon resonance. In Figure 7 the
sensorgrams reﬂecting the interactions of NBD1 with the R
and   CK2 subunits, respectively, are presented. They
demonstrate that although both subunits interact with NBD1,
either wild type or ∆F508, in both cases the mutant binds
better than wild type, the tightest interaction being the one
between NBD1 ∆F508 and CK2 R-subunit. As reported in
Table 1 this interaction is characterized by a quite low KD
FIGURE 6: Positive cooperative effect of NBD1 phosphorylation by
CK2 holoenzyme in the presence of wild-type and ∆F508 peptide.
Phosphorylation condition at increasing concentration of the
substrate and evaluation of the phosphate incorporated after
SDS-PAGE were performed as described in the Experimental
Procedures. The data represent the means obtained from experiments
run in triplicate with SD never exceeding 20%. (A, B) Murine
NBD1 either alone (control) or in the presence of wild-type and
∆F508 mutated peptides (80 µM). The corresponding autoradio-
grams are shown in (A). (C) Human NBD1 in the presence of wild-
type and ∆F508 mutated synthetic peptides (80 µM). (D) Calmo-
dulin in the presence of ∆F508 mutated peptide (80 µM).
FIGURE 7: SPR analysis of the interaction of mouse NBD1 wild
type and ∆F508 with human CK2 subunits. Representative sen-
sorgrams obtained as detailed in the Experimental Procedures by
injection of 15 µM NBD1 wt and NBD1 ∆F508 over a sensor
surface containing 1600 RU of immobilized CK2R (A) and of 10
µM NBD1 wt and NBD1 ∆F508 over a sensor surface containing
1660 RU of immobilized CK2  (B).
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for the  -subunit itself (40.8 nM) whose complex with CK2R
is extremely stable in vitro, requiring denaturing conditions
for dissociation (34). In contrast, the interaction of NBD1
wild type with CK2R is signiﬁcantly weaker (KD ) 2470
nM), the difference being mainly accounted for by an almost
1 order of magnitude lower association constant (ka ) 0.135
× 103 vs 0.96 × 103). This suggests that association with
CK2R involves the NBD1 segment affected by the ∆F508
mutation. Such a conclusion was strengthened by the
experiment illustrated in Figure 8, showing that the interac-
tion between CK2  - and R-subunits is weakened by the
CFTR peptide 506-518 ∆F, which also promotes NBD1
phosphorylation by CK2 holoenzyme but not by its shortened
derivative 509-518 which has lost the ability to evoke CK2
holoenzyme activity (see Figure 4).
DISCUSSION
A priori the main if not the only biochemical argument
suggesting a link between CF and protein kinase CK2 was
the presence in the NBD1 domain of CFTR of a phospho-
acceptor residue (S511) fulﬁlling the CK2 consensus
(S511yDEyr) in the close proximity of F508, i.e., the residue
whose single deletion (∆F508 or F508del) is the by far the
most common cause of cystic ﬁbrosis affecting around 75%
of diseased chromosomes. F508 is outside the sensu stricto
CK2 site (conventionally speciﬁed by acidic residues at
positions between n - 2 and n + 5( 19)), and its deletion
was not predicted to necessarily affect the proneness of S511
to CK2-mediated phosphorylation. Nevertheless, it is quite
reasonable to speculate that the deletion of such a bulky
hydrophobic side chain at position n - 3 with respect to the
target residue might have consequences on the phosphoac-
ceptor site conformation and therefore on its phosphorylation
efﬁciency by CK2.
The results presented corroborate the concept introduced
by Treharne and colleagues that functional links indeed exist
between CK2 and CFTR which are deeply affected by the
F508 deletion. Somewhat paradoxically however our ﬁndings
tend to exclude any phosphorylation of S511 by CK2 while
supporting the view that the sequence surrounding F508
represents, with respect to CK2, at the same time a docking
site and an allosteric effector whose dual function is increased
by F508 deletion.
Although in fact NBD1 is readily phosphorylated by CK2
catalytic subunit and even more by CK2 holoenzyme in the
presence of polylysine, S511 could not be found among the
phosphoresidues identiﬁed by MS analysis: these are S422
(either alone or together with S423) and S670, both fulﬁlling
the consensus sequence for CK2 and conserved in human
CFTR as well (see Table 2). Failure of CK2 to phosphorylate
S511 was also conﬁrmed by using a set of peptide substrates
variably reproducing the sequence around this residue: the
phosphorylation of all peptides either with naturally occurring
sequences or with suitable modiﬁcations was null or anyway
negligible as compared to that of full-length NBD1, with
the only partial exception of a phosphopeptide in which Y512
was replaced by phosphotyrosine to mimic a hypothetical
priming effect of Syk tyrosine kinase. Thus it is not clear
which are the negative determinant(s) preventing the phos-
Table 1: Binding Constants of Wild-Type and Mutated NBD1 for
CK2R Catalytic Subunit
a
analyte ka (M-1 s-1) × 103 kd (s-1) × 10-3 KD (nM)
NBD1 wt 0.135 0.335 2470.0
NBD1 ∆F508 0.961 0.0877 91.2
∆ wt 22.7 0.93 40.8
a BIAcore analysis of NBD1 wt and NBD1 ∆F508 to CK2R coupled
to the biosensor surface was performed as described in the Experimental
Procedures. The Langmuir 1:1 model was used to ﬁt kinetic data.
Association rates (ka), dissociation rates (kd), and dissociation constants
(KD ) kd/ka) are reported.   interaction values were from ref 29.
FIGURE 8: Effect of NBD1-derived synthetic peptides on the
interaction between CK2R and CK2  subunits. 22 nM CK2R
subunit was injected at a ﬂow rate of 10 µL/min over a sensor
surface containing 1660 RU of immobilized CK2 . The same
amount of CK2R was injected after an incubation of 10 min with
a ﬁxed amount (5 µM) of CFTR peptide 506-518 ∆F (A) and its
shortened derivative 509-518 (B). Similar results were obtained
with different concentrations of CK2R. Injections of 5 µM peptide
alone showed any RU alteration.






MQRS4PLEKASV intracellular domain yes






LVTS605KMEHLKK regulatory domain yes
FYGT629FSELQNL regulatory domain no
ANLT803ELDIYSR regulatory domain no
RRLS813QET816GLEISEEINEED regulatory domain no
LPLT990IFDFIQL intracellular domain yes
SILT1121TGEGEGR intracellular domain yes
AVNS1149SIDVDSL intracellular domain yes
GQMT1211VKDLTAK intracellular domain no
LLNT1263EGEIQID NBD2 no
GLRS1327VIEQFPG NBD2 yes
QAIS1443PSDRVKL intracellular domain yes
KEET1472EEEVQDT intracellular domain yes
a An acidic residue at position n + 3 was chosen as a minimum
requirement to identify bold-typed CK2 potential sites (19). Acidic
determinants are underlined.
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consensus sequence of CK2 and occupying an exposed
position in NBD1 (11).
The mode of NBD1 phosphorylation by CK2 is also
noteworthy: instead of being stimulated by the  -subunit as
in the case of the vast majority of CK2 substrates, phos-
phorylation of NBD1 is actually fully prevented by the
 -subunits, so that CK2 holoenzyme composed of two
catalytic and two  -subunits (which is the predominant form
of CK2 within the cell) is unable to phosphorylate NBD1
unless its activity is artiﬁcially triggered by the addition of
polylysine. This behavior is not unique to NBD1, being also
shared by a small subset of substrates, sometimes referred
to as “class II”, typically represented by calmodulin (20). It
is generally accepted that these substrates are particularly
susceptible to downregulation by CK2 , which in the case
of other substrates is instead overcome by concomitant
upregulation by the  -subunit, whose dual function was
recognized early (35, 36). Interestingly, the very same
peptides encompassing the F508 region of CFTR, which
proved unable to undergo phosphorylation, are nevertheless
able to overcome the inhibition by  -subunit, thereby evoking
NBD1 phosphorylation by CK2 holoenzyme. Our crucial
result is that such a stimulatory efﬁcacy is increased by the
deletion of F508 in a fashion which is consistent with an
allosteric cooperative effect on CK2 holoenzyme activity.
Higher efﬁcacy of ∆F508 peptides as compared to wild-
type ones as CK2 holoenzyme activators is also consistent
with the higher afﬁnity binding to CK2 subunits of NBD1
∆F508 as compared to wild type, as revealed by SPR
experiments (see Figure 7 and Table 1). The capability of
these surface-located peptides derived from NBD1 of CFTR
to ﬁnely tune CK2 targeting is highlighted by the divergent
effects they exert on the isolated catalytic subunit of CK2
as compared to CK2 holoenzyme and by their dependence
on the nature of the phosphorylatable substrate (see Figure
5). It should be mentioned in this respect that, although the
in vivo occurrence of reversible CK2 holoenzyme dissocia-
tion is still a matter of conjecture, the presence of CK2
catalytic subunits not combined with the  -subunits in
different kinds of cells has been unambiguously proven (e.g.,
ref 37).
While the mechanism(s) by which NBD1 interacts with
CK2 is (are) still a matter of conjecture, we have to assume
on the one hand that the NBD1 region implicated is the
one encompassing F508 since the deletion of this residue
dramatically enhances the binding efﬁciency and on the
other that such a binding perturbs the interactions between
CK2R and CK2  in such a way that only downregulation
by the  -subunits is abrogated, while the stimulatory
efﬁcacy of this subunit is unaffected. This bipartite
conclusion is supported by the experiments of Figure 5A
showing that the NBD1 peptides remove inhibition but
not stimulation exerted by the  -subunit on the phospho-
rylation of different substrates which in general is actually
enhanced by the ∆F508 peptide.
While our mechanistic study reveals a scenario where the
exposed loop between NBD1 helices 3 and 4 represents a
CK2 docking site whose capability to recruit CK2R is
enhanced by the ∆F508 mutation and correlates with
increased activity of CK2 holoenzyme toward a number of
its protein targets, the identity of these substrates and the
physiological signiﬁcance of their phosphorylation remain
a matter of conjecture.
The ﬁrst candidate of course would be CFTR itself which
bears around 20 residues fulﬁlling the consensus sequence
of CK2 which are spread out in nearly all its functional
domains, with special reference to NBD1, the regulatory
domain (R), and NBD2 (see Table 2). As mentioned above,
we have found that S422 in NBD1 is readily phosphorylated
by CK2 in vitro: this residue is also phosphorylated by PKA
and its phosphorylation has been shown to have an effect
on CFTR activity (38) and to confer order on residues
420-428 (11) collectively referred to as the “regulatory
insertion”. Curiously, there are intriguing residues in CFTR
which share the features for being targets of both CK2 and
PKA besides S670 (see Figure 2) whose phosphorylation
by PKA affects CFTR activity (39). Of special interest in
this respect may be residue S813 in the R domain, one of
the four major in vivo phosphosites thought to be responsible
for CFTR channel activation (40). Phosphorylation of S813
by CK2 can be primed by previous phosphorylation of T816,
which in turn displays an outstanding CK2 consensus
(S813qET816glEsEEinEED).
The F508 deletion in CFTR is highly prevalent, being
carried by 1 in 25 humans of European descent. It has
long been speculated that some biological advantage must
have accrued in the past for carriers of this mutation. The
paradox is that such an advantage cannot be easily
reconciled with the apparently normal health and CFTR
ion channel function observed in carriers. However, should
the F508 deleted surface of the mutant CFTR have a
positive role, as our data predict, then a new scenario
arises. Current dogma holds that loss of F508 creates a
CFTR that does not trafﬁc normally and degrades rapidly.
Thus in this view the sole impact of ∆F508 is disrupted
ion transport. Our data suggest that a ∆F508 CFTR protein
could regulate CK2 targeting in multiple systems. An
appealing speculation would be that in CF cells, either
homozygous or heterozygous for the CFTR ∆F508 gene,
activation of CK2 results in the phosphorylation and
upregulation of chaperone proteins committed to the
folding and processing of CFTR (or other proteins).
Indeed, several chaperones are among CK2 targets (19),
and a number of proteins committed to CFTR processing
have been recently found in a CK2  subunit interactome
isolated from rat brain (41). Interestingly, the phospho-
rylation of HSP90 which is unaffected by the wt peptide
is stimulated by the ∆F508 peptide (see Figure 5). It will
be interesting to extend this analysis to other proteins
involved in the processing and trafﬁcking of CFTR,
notably HSP70, calnexin, and histone deacetylase, to see
if their phosphorylation by CK2 is stimulated by the NBD1
peptides described here. Also, the identiﬁcation of CK2
substrates in the macromolecular complex recruited by
CFTR at the cell membrane may help to understand the
functional consequences of the biochemical interactions
disclosed by our work. This notion has received support
from recent experiments showing that an epithelial sodium
channel controlled by CFTR is CK2 regulated (42).
It should be ﬁnally remembered that most of the experi-
ments described here were performed with mouse NBD1,
because its ∆F508 mutant was available to us while the
human ∆F508 mutant was not. All of the critical points,
7934 Biochemistry, Vol. 47, No. 30, 2008 Pagano et al.however, notably the mode of phosphorylation by CK2R and
holoenzyme, identiﬁcation of the phosphorylated residues,
SPR monitored interaction with CK2 subunits, and suscep-
tibility to modulation by CFTR derived peptides, were also
assessed with wild-type human NBD1, obtaining substan-
tially identical results. This outcome and the observation that
the sequence of the stimulatory peptides encompassing
residues 500-518 is identical in human and in mouse NBD1
corroborate the concept that the information provided with
mouse CFTR also applies to human CFTR.
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